Market Revenue Cystic Fibrosis (CF) Therapeutics Industry

Cystic Fibrosis (CF) Therapeutics Industry Specification, Product
Category, Status and Prospect Till 2025
“Cystic Fibrosis (CF) Therapeutics Market is expected to be valued at USD 13.9
billion with CAGR of 16.7% over the forecast period. Cystic fibrosis (CF) is a
severe disease that causes overall damage to lungs, digestive systems and
other organs in the body.”
The global Cystic Fibrosis (CF) Therapeutics Market is expected to be valued at USD 13.9 billion with CAGR of
16.7% over the forecast period. Cystic fibrosis (CF) is a severe disease that causes overall damage to lungs,
digestive systems and other organs in the body. In this state, CF affects the cells that are responsible for sweat,
mucus digestive and fluid juices. These juices are normally thin and slippery but patients suffering from cystic
fibrosis experience thick blockage in lungs and other organs, as this affects the cells that regulate digestive and
fluid juices causing them to become an obstacle rather than carriers. The cells instead of acting as a lubricant
become sticky and thick, thus blocking up lungs, pancreas and other organs in the body. Medically this disease
is termed as mucoviscidosis.
The major driving factors of this market rely significantly on extensive R&D. As the ongoing R&D activities have
boosted the CF therapeutics market and witnesses a lucrative growth in the upcoming years. The other driving
factors like awareness for cystic fibrosis therapy, technological advancements in R&D attribute to the success
of market growth. However, high costs of treatment and R&D, entangled pathophysiology, rising rate in genetic
mutation are some factors that may cause to hinder the market growth. On the basis of therapeutics, the global
market is segmented into pulmozyme, TOBI, kalydeco, Cayston, Arikace, Aeroquin and others. Cystic Fibrosis
Trans membrane Conductance Regulators (CFTR) modulators treat the root cause of disease rather than
symptoms, resulting in improving the lives of patients. Kalydeco is the first CFTR modulator to enter the market
and had a large impact on the value of market though it treated a small proportion of CF patients.
Request Sample Copy of this Market Research @
https://www.millioninsights.com/industry-reports/cystic-fibrosis-cf-therapeutics-market/request-sample